Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer

M. K. Bos*, S. W. Lam, G. Motta, J. C.A. Helmijr, C. M. Beaufort, E. de Jonge, J. W.M. Martens, E. Boven, M. P.H.M. Jansen, A. Jager, S. Sleijfer

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

38 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology